Catheter Ablation Trial Criteria For AF Therapy Clarified In FDA Guidance
This article was originally published in The Gray Sheet
Executive Summary
Commercialization of CryoCath's catheter ablation system to treat atrial fibrillation could be delayed up to six months due to FDA follow-up data recommendations
You may also be interested in...
Cryoablation Safer Than RF In Treating Atrial Fib, Trial Sponsor Says
CryoCath expects to learn by April whether FDA will require a follow-up period of longer than six months for a pivotal study of the Arctic Front ablation catheter to treat chronic atrial fibrillation
Cryoablation Safer Than RF In Treating Atrial Fib, Trial Sponsor Says
CryoCath expects to learn by April whether FDA will require a follow-up period of longer than six months for a pivotal study of the Arctic Front ablation catheter to treat chronic atrial fibrillation
St. Jude Augments AF Division With $47 Mil. Irvine Biomedical Purchase
St. Jude will evaluate whether to pursue an atrial fibrillation indication for Irvine Biomedical, Inc.'s Therapy, Dual 8 and Cooled-Tip ablation catheters